

### **SUMMARY OF EXAMINER INTERVIEW**

Applicants thank Examiner Sims for being available for, and participating in, a telephonic interview that occurred on February 2, 2010, in which the Applicants' representative discussed the differences between the claimed invention and the references cited (e.g., U.S. Publication No. 2002/0110823 to Hogan) in support of the 35 U.S.C. § 103(a) rejection of independent claims 1, 18, and 35. Specifically, Applicants' representative brought to the attention of the Examiner that inventive aspects of the present invention are now recited by the claims and are not found in the combination of references as cited. For instance, an inventive aspect that was discussed involved the following inventive process: (a) incident to determining that the genetic test result value correlates to polymorphism values, accessing the second data set; (b) utilizing the second data set to determine whether a risk of damage from not administering the clinical agent is greater than the risk of damage by lowering the dosage of the clinical agent; and (c) indicating a lower dosage of the clinical agent be prescribed when the risk of damage is less than not administering the clinical agent. During the discussion, the Examiner indicated that this amendment and the others discussed may help clarify the distinction between the claimed invention and the cited references. Accordingly, changes have been implemented in the appropriate claims in order to advance prosecution.